Needle-free ZOMACTON delivery can
help a broad range of patients1



Needle-free ZOMACTON delivery can
help a broad range of patients1








Ensure your patients administer needle-free ZOMACTON with confidence.
Download the ZOMA-Jet 10 Instructions for Use now  »

Treat MORE growth-related conditions than ever before1

Needle-free ZOMA-Jet 10 delivers ZOMACTON, a proven somatropin therapy indicated for the treatment of:

Pediatric patients with

  • Growth failure due to inadequate secretion of endogenous growth hormone (GH)
  • Short stature associated with Turner syndrome
  • Idiopathic short stature
  • Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency
  • Short stature born small for gestational age (SGA) with no catch-up growth by 2 to 4 years

Adult patients

  • Replacement of endogenous GH in adults with GH deficiency1



When it comes to growth, ZOMACTON has been proven to perform1


ZOMACTON was studied in pediatric patients with short stature due to GHD1


Primary objective: Determine the impact ZOMACTON had on height velocity in pediatric patients


Methodology: 2‐year, open‐label, multicenter study of 164 pediatric patients with short stature due to GHD conducted in the United States and Israel

  • Subjects ranged from 2.1 to 17.7 years of age, with a mean age of 10.8 years
  • Height velocity was calculated at 24 weeks and after 12 months of therapy across 3 treatment groups:

–Naïve Type I: serum GH <10 ng/mL in response to at least 2 provocative pharmacological tests (n=68)

–Naïve Type II: integrated GH level <3.5 ng/mL with or without at least 1 serum GH ≥10 ng/mL (n=60)

–Non‐naïve: treated with GH up to study Day 1, or previously treated and discontinued GH treatment at least 6 months prior to study Day 1 (n=36)


Results:



24 Weeks after initiating ZOMACTON therapy


Patients from each treatment group experienced a mean cumulative increase in height velocity from baseline at 24 weeks1

—Naïve Type I: 2.6 inches (P<0.01)—Naïve Type II: 1.8 inches (P<0.01)—Non-naïve: 2.5 inches (P<0.01)

—Naïve Type I: 2.6 inches (P<0.01)
—Naïve Type II: 1.8 inches (P<0.01)
—Non-naïve: 2.5 inches (P<0.01)



For additional information on other indications, please see the full Prescribing Information.

The treatment flexibility your patients need



ZOMACTON is available in 2 dosing strengths1:

  • 5 mg (accompanying diluent preserved with benzyl alcohol*)
  • 10 mg (accompanying diluent preserved with metacresol)

*Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative: Serious and fatal adverse reactions can occur in neonates and infants treated with benzyl alcohol-preserved drugs, including the diluent for ZOMACTON 5 mg. If administering ZOMACTON 5 mg to infants, reconstitute with 0.9% sodium chloride injection. Do not use in patients with hypersensitivity, pregnant or lactating women.


There are 2 dose-delivery options1:

  • Needle-free ZOMACTON delivery with ZOMA-Jet
  • ZOMACTON vial and syringe


A different ZOMA-Jet is available for delivery of ZOMACTON 5 mg.


The treatment flexibility your patients need



ZOMACTON is available in 2 dosing strengths1:

  • 5 mg (accompanying diluent preserved with benzyl alcohol*)
  • 10 mg (accompanying diluent preserved with metacresol)

*Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative: Serious and fatal adverse reactions can occur in neonates and infants treated with benzyl alcohol-preserved drugs, including the diluent for ZOMACTON 5 mg. If administering ZOMACTON 5 mg to infants, reconstitute with 0.9% sodium chloride injection. Do not use in patients with hypersensitivity, pregnant or lactating women.


There are 2 dose-delivery options1:

  • Needle-free ZOMACTON delivery with ZOMA-Jet
  • ZOMACTON 10 mgvial and syringe


A different ZOMA-Jet is available for delivery of ZOMACTON 5 mg.


Delivering each dose of ZOMACTON accurately


PEDIATRIC DOSING

PEDIATRIC DOSING


Divide the calculated weekly dosage into equal doses given either 3, 6, or 7 days per week1

INDICATION DOSAGE DOSAGE
GH Deficiency 0.18 mg/kg/week to 0.3 mg/kg/week (0.026 mg/kg/day to 0.043 mg/kg/day) 0.18 mg/kg/week to 0.3 mg/kg/week (0.026 mg/kg/day to 0.043 mg/kg/day)
Turner Syndrome Up to 0.375 mg/kg/week (up to 0.054 mg/kg/day) Up to 0.375 mg/kg/week (up to 0.054 mg/kg/day)
Idiopathic Short Stature Up to 0.37 mg/kg/week (up to 0.053 mg/kg/day) Up to 0.37 mg/kg/week (up to 0.053 mg/kg/day)
SHOX Deficiency 0.35 mg/kg/week (0.050 mg/kg/day) 0.35 mg/kg/week (0.050 mg/kg/day)
Small for Gestational Age (SGA) Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day) Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day)



In very short pediatric patients, HSDS less than -3, and older pubertal pediatric patients, consider initiating treatment with a larger dose of ZOMACTON (up to 0.067 mg/kg/day). Consider a gradual reduction in dosage if substantial catch-up growth is observed during the first few years of therapy. In pediatric patients less than 4 years of age with less severe short stature and baseline HSDS values between -2 and -3, consider initiating treatment at 0.033 mg/kg/day and titrate the dose as needed.1



ADULT DOSING

ADULT DOSING


Either of the following 2 dosing regimens may be used1:

NON–WEIGHT-BASED DOSING

Initiate with a dose of approximately 0.2 mg/day (range, 0.15 mg/day-0.3 mg/day), and increase the dose every 1-2 months by increments of approximately 0.1 mg/day-0.2 mg/day, according to individual patient requirements

WEIGHT-BASED DOSING
(not recommended for obese patients)

Initiate at 0.006 mg/kg daily, and increase the dose according to individual patient requirements to a maximum of 0.0125 mg/kg daily

Either of the following 2 dosing regimens may be used1:

NON–WEIGHT-BASED DOSING

Initiate with a dose of approximately 0.2 mg/day (range, 0.15 mg/day-0.3 mg/day), and increase the dose every 1-2 months by increments of approximately 0.1 mg/day-0.2 mg/day, according to individual patient requirements


WEIGHT-BASED DOSING
(not recommended for obese patients)

Initiate at 0.006 mg/kg daily, and increase the dose according to individual patient requirements to a maximum of 0.0125 mg/kg daily



A NEEDLE-FREE EXPERIENCE
WITH ZOMA-JET 10

Grant patients their wish for no needles and remove a barrier to adherence

COMMITMENT TO COVERAGE

Because coverage is our priority, we have access programs designed to help your patients start and stay on ZOMACTON

LEARN MORE LEARN MORE


As long as medically necessary.

A NEEDLE-FREE EXPERIENCE
WITH ZOMA-JET 10

Grant patients their wish for no needles and remove a barrier to nonadherence

LEARN MORE



COMMITMENT TO COVERAGE

Because coverage is our priority, we have access programs designed to help your patients start and stay on ZOMACTON

LEARN MORE

‡As long as medically necessary.

Reference: 1. ZOMACTON [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.


PLEASE SEE IMPORTANT SAFETY INFORMATION AND FULL PRESCRIBING INFORMATION.
PLEASE SEE IMPORTANT SAFETY INFORMATION AND FULL PRESCRIBING INFORMATION.
+
PLEASE SEE IMPORTANT SAFETY INFORMATION AND FULL PRESCRIBING INFORMATION.
PLEASE SEE IMPORTANT SAFETY INFORMATION AND FULL PRESCRIBING INFORMATION.
-+